Summit Securities Group LLC Cuts Position in Merck & Co., Inc. $MRK

Summit Securities Group LLC decreased its position in Merck & Co., Inc. (NYSE:MRK) by 72.4% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 8,238 shares of the company’s stock after selling 21,563 shares during the quarter. Summit Securities Group LLC’s holdings in Merck & Co., Inc. were worth $991,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also added to or reduced their stakes in the company. Waterfront Wealth Inc. bought a new position in shares of Merck & Co., Inc. during the 1st quarter valued at approximately $245,000. Meadow Creek Wealth Advisors LLC grew its holdings in shares of Merck & Co., Inc. by 11.0% in the first quarter. Meadow Creek Wealth Advisors LLC now owns 12,379 shares of the company’s stock valued at $1,489,000 after purchasing an additional 1,229 shares in the last quarter. Main Street Research LLC grew its holdings in shares of Merck & Co., Inc. by 22.3% in the first quarter. Main Street Research LLC now owns 9,521 shares of the company’s stock valued at $1,145,000 after purchasing an additional 1,737 shares in the last quarter. First Horizon Corp increased its position in Merck & Co., Inc. by 38.1% in the first quarter. First Horizon Corp now owns 160,464 shares of the company’s stock worth $19,302,000 after purchasing an additional 44,269 shares during the last quarter. Finally, Valued Wealth Advisors LLC increased its position in Merck & Co., Inc. by 61.0% in the first quarter. Valued Wealth Advisors LLC now owns 715 shares of the company’s stock worth $87,000 after purchasing an additional 271 shares during the last quarter. Institutional investors own 76.07% of the company’s stock.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck’s KEYTRUDA franchise got a boost from recent U.S. and EU approvals in breast and bladder cancer, expanding its use in hard-to-treat tumors and strengthening the company’s oncology growth story. Article Title
• Positive Sentiment: Merck also reached a new access agreement for its HIV treatment, IDVYNSO, which could modestly improve market access and commercial momentum for the product. Article Title
• Positive Sentiment: Several analysts remain constructive on Merck, including recent price-target increases from RBC and Wells Fargo, reflecting confidence in the company’s pipeline and KEYTRUDA-driven earnings power. Article Title
• Neutral Sentiment: Merck has been attracting elevated investor attention, but the related coverage is more about monitoring the stock’s setup than a new business catalyst. Article Title
• Neutral Sentiment: A market report on Southeast Asia oncology drug access listed Merck among peer companies, highlighting the broader opportunity for cancer therapy access but not pointing to a company-specific development. Article Title
• Negative Sentiment: Morgan Stanley trimmed its price target to $113 and kept an equal-weight rating, signaling limited near-term upside from current levels and reinforcing valuation caution. Article Title

Analyst Ratings Changes

Several research firms have commented on MRK. Wells Fargo & Company increased their price objective on shares of Merck & Co., Inc. from $145.00 to $150.00 and gave the company an “overweight” rating in a research report on Wednesday. CICC Research started coverage on shares of Merck & Co., Inc. in a report on Wednesday, June 24th. They issued an “outperform” rating and a $138.00 target price on the stock. Bank of America boosted their target price on shares of Merck & Co., Inc. from $130.00 to $141.00 and gave the stock a “buy” rating in a report on Tuesday, June 30th. Zacks Research upgraded shares of Merck & Co., Inc. from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 17th. Finally, Scotiabank increased their price target on shares of Merck & Co., Inc. from $136.00 to $155.00 and gave the company a “sector outperform” rating in a report on Tuesday, June 30th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and seven have given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $132.72.

Merck & Co., Inc. Trading Down 0.7%

MRK stock opened at $125.17 on Friday. The company has a quick ratio of 1.06, a current ratio of 1.30 and a debt-to-equity ratio of 1.02. Merck & Co., Inc. has a twelve month low of $76.66 and a twelve month high of $130.29. The stock has a market capitalization of $309.14 billion, a price-to-earnings ratio of 35.26, a price-to-earnings-growth ratio of 2.69 and a beta of 0.19. The firm’s fifty day simple moving average is $118.57 and its two-hundred day simple moving average is $116.23.

Merck & Co., Inc. (NYSE:MRK) last announced its earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share for the quarter, beating the consensus estimate of ($1.47) by $0.19. The business had revenue of $16.29 billion for the quarter, compared to the consensus estimate of $15.85 billion. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The business’s revenue for the quarter was up 4.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.22 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. As a group, analysts anticipate that Merck & Co., Inc. will post 5.19 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, July 8th. Investors of record on Monday, June 15th were given a $0.85 dividend. This represents a $3.40 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date of this dividend was Monday, June 15th. Merck & Co., Inc.’s dividend payout ratio is 95.77%.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.